Allistair A Abraham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8147811/publications.pdf

Version: 2024-02-01

48	1,177	393982	395343
papers	citations	19 h-index	33 g-index

49	49	49	1680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood, 2016, 128, 2561-2567.	0.6	174
2	Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. American Journal of Hematology, 2015, 90, 1093-1098.	2.0	109
3	SARS-CoV-2â€“specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood, 2020, 136, 2905-2917.	0.6	108
4	Relationship between Mixed Donorâ€“Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 2178-2183.	2.0	74
5	Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. Biology of Blood and Marrow Transplantation, 2017, 23, 1587-1592.	2.0	58
6	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal of Hematology, 2019, 94, 446-454.	2.0	56
7	Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1171-1185.	0.9	50
8	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biology of Blood and Marrow Transplantation, 2017, 23, 1342-1349.	2.0	50
9	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	1.7	43
10	Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood, 2021, 138, 932-941.	0.6	37
11	Clofarabine salvage therapy for refractory highâ€risk langerhans cell histiocytosis. Pediatric Blood and Cancer, 2013, 60, E19-22.	0.8	34
12	Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. Pediatric Blood and Cancer, 2015, 62, 1285-1287.	0.8	33
13	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30
14	Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?. British Journal of Haematology, 2020, 189, 408-423.	1.2	29
15	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 2019, 3, 2057-2068.	2.5	27
16	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 301-306.	2.0	27
17	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
18	Using Fludarabine to Reduce Exposure to Alkylating Agents in Children with Sickle Cell Disease Receiving Busulfan, Cyclophosphamide, and Antithymocyte Globulin Transplant Conditioning: Results of a Dose De-Escalation Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 900-905.	2.0	24

#	Article	IF	Citations
19	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206.	2.5	21
20	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
21	When there is no match, the game is not over: Alternative donor options for hematopoietic stem cell transplantation in sickle cell disease. Seminars in Hematology, 2018, 55, 94-101.	1.8	15
22	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	2.5	14
23	Cellular therapy for sickle cell disease. Cytotherapy, 2016, 18, 1360-1369.	0.3	13
24	Cerebral Blood Flow and Marrow Diffusion Alterations in Children with Sickle Cell Anemia after Bone Marrow Transplantation and Transfusion. American Journal of Neuroradiology, 2018, 39, 2132-2139.	1.2	11
25	Alternative Donor/Unrelated Donor Transplants for the Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 123-153.	0.8	10
26	Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologistsâ€™ practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study. Pediatric Blood and Cancer, 2021, 68, e28861.	0.8	9
27	Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2022, 24, 249-261.	0.3	9
28	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). Blood, 2015, 126, 543-543.	0.6	8
29	Homozygous Î±â€thalassemia: Challenges surrounding early identification, treatment, and cure. Pediatric Blood and Cancer, 2017, 64, 151-155.	0.8	7
30	Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke. Transplantation and Cellular Therapy, 2021, 27, 1018.e1-1018.e9.	0.6	7
31	Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation. Transfusion Medicine Reviews, 2016, 30, 202-208.	0.9	6
32	Lentiviral Transfer of Î³-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine Î²-Thalassemia. Molecular Therapy, 2017, 25, 593-605.	3.7	6
33	Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLAâ€matched haematopoietic cell transplant for sickle cell disease. British Journal of Haematology, 2020, 189, 162-170.	1.2	6
34	Increased Engraftment of Human Short Term Repopulating Hematopoietic Cells in NOD/SCID/IL2rÎ³null Mice by Lentiviral Expression of NUP98-HOXA10HD. PLoS ONE, 2016, 11, e0147059.	1.1	6
35	Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27601.	0.8	5
36	A Multi-Institutional Retrospective Data Analysis of Hematopoietic Cell Transplantation for Less Severe Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S95.	2.0	3

#	Article	IF	Citations
37	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. Cytotherapy, 2022, 24, 884-891.	0.3	3
38	Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease. Journal of Clinical Medicine, 2022, 11, 3856.	1.0	3
39	Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplantation and Cellular Therapy, 2022, 28, 174.e1-174.e5.	0.6	2
40	An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. Cytotherapy, 2022, 24, 385-392.	0.3	2
41	Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease. , 2018, , 303-328.		1
42	Non-Myeloablative Conditioning Targeting Host Immunosuppression Is Successful in Matched Sibling Donor Stem Cell Transplantation for Hemoglobinopathies in Children. Blood, 2014, 124, 3873-3873.	0.6	1
43	Engraftment in utero: itâ€™s all in the delivery. Blood, 2019, 134, 1889-1890.	0.6	0
44	Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease. , 2018, , 283-302.		0
45	Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR). Blood, 2021, 138, 3030-3030.	0.6	0
46	Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial. Blood, 2021, 138, 2036-2036.	0.6	0
47	Disease Burden and Pre-Transplant Health-Related Quality of Life in Pediatric Sickle Cell Disease Patients Receiving Nonmyeloablative HLA-Identical Sibling Donor Transplantation. Blood, 2021, 138, 4073-4073.	0.6	0
48	Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood, 2020, 136, 33-33.	0.6	0